The chromatin regulatory system orchestrates gene expression–the turning on and off of genes–which is fundamental to how all our cells function. Breakdowns in this system lead to a wide range of diseases impacting millions of patients. Understanding the mechanism of how this system works could lead to an entirely new class of therapeutics. To our […]

We intend to focus on businesses primarily operating in the health care and health care provider space in North America and Asia-Pacific. Possible targets may include hospitals or hospital networks, specialty clinics chains, chronic disease health care service providers, telemedicine/digital health providers and/or associated technology/platform enablers, or artificial intelligence/big data enabled diagnostic providers.  We believe the […]

  We intend to focus our search for an initial business combination on companies within the broader consumer technology ecosystem that are either consumer-facing or support the infrastructure of consumer applications (“apps”) with enterprise valuations in an approximate valuation range of $1.0 billion to $3.0 billion. We intend to specifically focus on companies that have created, or […]

We intend to focus our search for a target business in the energy value chain in North America with a particular focus on opportunities aligned with energy transition and sustainability themes.  Our sponsor is an affiliate of a private investment fund managed by Apollo. Leon Black, Joshua Harris and Marc Rowan, Apollo’s managing partners, have […]

  We are a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. We use our proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. This […]

We intend to capitalize on the ability of our management team to identify, acquire and manage a market-leading business that may provide opportunities for attractive risk-adjusted returns. We believe the expertise of our management team will allow us to identify potential acquisition targets with attractive risk-adjusted returns across a diverse set of industries and geographies. […]

We intend to concentrate our efforts in identifying businesses in the governance, risk, and compliance (“GRC”) and legal technology and software (collectively, “GRCL”) sectors with an enterprise value of about $750 million to $2 billion. We believe the GRCL universe is comprised of hundreds of private companies attractive for today’s public market environment. Our sponsor […]

We intend to focus our search for a target business operating in the restaurant, hospitality and related technology and service sectors (our “Target Sectors”) globally. Our management team, led by co-CEOs Dave Pace and Andy Pforzheimer, with Greg Golkin as president. and Chris Bradley as CFO, Officer, bring a unique combination of executive, operating, investing, financial and […]

We intend to focus on businesses that have their primary operations located in North America in the healthcare industry. it is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma, medical technology, digital health, and healthcare […]

KINS Technology Group is focused on identifying and acquiring transformative technology businesses that are shaping the digital future and creating a new paradigm of communications and computing. The five technology pillars of this new paradigm are next generation connectivity, open software, edge-cloud computing, predictive data analytics, and immersive media technologies.   We believe the world is […]